Giada Lavigna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Giada Lavigna has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Roberto Chiesa
Department of Neuroscience, Laboratory of Prion Neurobiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
3 shared publications - David A. Harris
Affiliation Department of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States of America
2 shared publications Erin Flaherty
Department of Microbiology, Immunology, and Pathology, Prion Research Center, Colorado State University, Fort Collins, Colorado, USA
2 shared publications- Isabel C. Orbe
Department of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States of America
2 shared publications - Jean R. P. Gatdula
Department of Biochemistry and Cell Biology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts 02118, United States of America
2 shared publications - Nadia A. Mirza-Romero
Department of Biochemistry & Cell Biology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA
2 shared publications
Latest Publications
- Open Access
Temperature homeostasis disruption and hypothalamic alterations in experimental drug‐resistant epilepsy
Objective: Elevated body temperature may increase seizure risk, yet the relationship between thermoregulation and seizures, as well as the underlying mechanisms, remains poorly understood. We investigated whether thermoregulatory control is altered in experimental temporal lobe epilepsy (TLE), as such impairment could reduce the ability of affected individuals to adapt to environmental temperature changes. Methods: Using an adult mouse model of temporal lobe epilepsy (TLE), we longitudinally measured brain temperature before and after epilepsy onset using 7 T 1 H‐magnetic resonance spectroscopy thermometry. The temporal relationship between spontaneous seizures and body temperature fluctuations was assessed using electroencephalographic recordings combined with implanted temperature probes under controlled environmental conditions. Neuronal density, glial reactivity, and transcriptomic profiles were examined in hypothalamic temperature‐sensing regions (ventromedial preoptic nucleus [VMPO] and dorsomedial nucleus [DMD]) in epileptic mice and sham mice. Hypothalamic volume was assessed by magnetic resonance imaging (MRI) in both mice and people with epilepsy (PWE). Serum thyroid‐stimulating hormone (TSH), T3, and T4 concentrations were measured as indices of hypothalamic–pituitary–thyroid (HPT) axis activity and metabolic thermogenesis. Results: Hippocampal temperature increased by ~.5–1.5°C prior to epilepsy onset (3 days postkainate) and remained elevated during chronic epilepsy (1.5 months postkainate). Acutely, body temperature rose from 15 min before to 15 min after spontaneous seizures. Serum T3 and T4 levels were reduced by ~50% without compensatory TSH elevation, indicating HPT axis dysregulation in epileptic mice. Neuronal density in VMPO and DMD decreased by ~20% in chronic epileptic mice versus sham mice ( p < .05), accompanied by induction of FosB, immune/inflammatory pathways, and glia reactivity. MRI revealed reduced hypothalamic volume in epileptic mice ( p < .05), paralleling findings in PWE. Significance: Thermoregulatory control is impaired in experimental TLE and is associated with neuronal loss and inflammation in hypothalamic temperature‐sensing regions. These findings reveal a link between thermoregulatory dysfunction and epilepsy and highlight that alterations in temperature homeostasis may interact with mechanisms underlying seizure generation.
Open AccessTemperature homeostasis disruption and hypothalamic alterations in experimental drug‐resistant epilepsy
Objective: Elevated body temperature may increase seizure risk, yet the relationship between thermoregulation and seizures, as well as the underlying mechanisms, remains poorly understood. We investigated whether thermoregulatory control is altered in experimental temporal lobe epilepsy (TLE), as such impairment could reduce the ability of affected individuals to adapt to environmental temperature changes. Methods: Using an adult mouse model of temporal lobe epilepsy (TLE), we longitudinally measured brain temperature before and after epilepsy onset using 7 T 1 H‐magnetic resonance spectroscopy thermometry. The temporal relationship between spontaneous seizures and body temperature fluctuations was assessed using electroencephalographic recordings combined with implanted temperature probes under controlled environmental conditions. Neuronal density, glial reactivity, and transcriptomic profiles were examined in hypothalamic temperature‐sensing regions (ventromedial preoptic nucleus [VMPO] and dorsomedial nucleus [DMD]) in epileptic mice and sham mice. Hypothalamic volume was assessed by magnetic resonance imaging (MRI) in both mice and people with epilepsy (PWE). Serum thyroid‐stimulating hormone (TSH), T3, and T4 concentrations were measured as indices of hypothalamic–pituitary–thyroid (HPT) axis activity and metabolic thermogenesis. Results: Hippocampal temperature increased by ~.5–1.5°C prior to epilepsy onset (3 days postkainate) and remained elevated during chronic epilepsy (1.5 months postkainate). Acutely, body temperature rose from 15 min before to 15 min after spontaneous seizures. Serum T3 and T4 levels were reduced by ~50% without compensatory TSH elevation, indicating HPT axis dysregulation in epileptic mice. Neuronal density in VMPO and DMD decreased by ~20% in chronic epileptic mice versus sham mice ( p < .05), accompanied by induction of FosB, immune/inflammatory pathways, and glia reactivity. MRI revealed reduced hypothalamic volume in epileptic mice ( p < .05), paralleling findings in PWE. Significance: Thermoregulatory control is impaired in experimental TLE and is associated with neuronal loss and inflammation in hypothalamic temperature‐sensing regions. These findings reveal a link between thermoregulatory dysfunction and epilepsy and highlight that alterations in temperature homeostasis may interact with mechanisms underlying seizure generation.
- Open Access
- 13 December 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (2) , 111050
Enhanced lysosomal activity prevents infection with PrPSc and the seeding activity of α-synuclein & tau prions
- 13 December 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (2) , 111050
Open AccessEnhanced lysosomal activity prevents infection with PrPSc and the seeding activity of α-synuclein & tau prions
- Open Access
Lysosomal Enhancement Prevents Infection with PrP Sc , α-Synuclein & Tau Prions
Prion diseases are fatal neurodegenerative diseases of humans and other mammals with no current treatment options. Here, we describe the characterization of a novel anti-prion compound, elacridar (GW120918), which has sub-micromolar activity in assays of prion infection, propagation and toxicity. Elacridar acts at an early step in the prion infection process, enhancing degradation of newly formed PrP Sc . The lysosome is the likely site of elacridars anti-prion effects, based on transcriptomic analysis and the use of functional lysosomal probes. Elacridar alters gene expression networks controlling lysosomal sterol and lipid metabolism but, unlike other lysosomotropic drugs, it prominently upregulates genes that control lysosomal pH. Surprisingly, these effects occur independently of TFEB nuclear translocation, suggesting novel regulatory mechanisms. The anti-prion effects of elacridar extend to α-synuclein and tau prions, highlighting lysosomal enhancement as a general strategy for the treatment of protein misfolding neurodegenerative diseases.
Open AccessLysosomal Enhancement Prevents Infection with PrP Sc , α-Synuclein & Tau Prions
Prion diseases are fatal neurodegenerative diseases of humans and other mammals with no current treatment options. Here, we describe the characterization of a novel anti-prion compound, elacridar (GW120918), which has sub-micromolar activity in assays of prion infection, propagation and toxicity. Elacridar acts at an early step in the prion infection process, enhancing degradation of newly formed PrP Sc . The lysosome is the likely site of elacridars anti-prion effects, based on transcriptomic analysis and the use of functional lysosomal probes. Elacridar alters gene expression networks controlling lysosomal sterol and lipid metabolism but, unlike other lysosomotropic drugs, it prominently upregulates genes that control lysosomal pH. Surprisingly, these effects occur independently of TFEB nuclear translocation, suggesting novel regulatory mechanisms. The anti-prion effects of elacridar extend to α-synuclein and tau prions, highlighting lysosomal enhancement as a general strategy for the treatment of protein misfolding neurodegenerative diseases.